query_id string | query string | document_ids string | answer string |
|---|---|---|---|
19315482_1 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 1 (An audio device for wireless audio playback, comprising: a wireless receiver configured to receive a sequence of audio blocks from a source device; a replay buffer configured to: store the sequence of audio blocks; det... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 1, and Smith further teaches the wireless transceiver limitation. |
19315482_2 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 1 (An audio device for wireless audio playback, comprising: a wireless receiver configured to receive a sequence of audio blocks from a source device; a replay buffer configured to: store the sequence of audio blocks; det... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 1, and Smith further teaches the replay buffer storing multiple audio blocks. |
19315482_3 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 1 (An audio device for wireless audio playback, comprising: a wireless receiver configured to receive a sequence of audio blocks from a source device; a replay buffer configured to: store the sequence of audio blocks; det... | ['US20030194004A1'] | It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine the teachings of a replay buffer configured to select filter coefficients from a plurality of octave-based frequency bands, as taught by Srinivasan, with the system as taught by Smith in v... |
19315482_4 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 1 (An audio device for wireless audio playback, comprising: a wireless receiver configured to receive a sequence of audio blocks from a source device; a replay buffer configured to: store the sequence of audio blocks; det... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 1, and Smith further teaches the fade-to-zero when error-free audio block is not detected, scaling the replacement blocks down in steps until reaching zero. |
19315482_5 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 1 (An audio device for wireless audio playback, comprising: a wireless receiver configured to receive a sequence of audio blocks from a source device; a replay buffer configured to: store the sequence of audio blocks; det... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 1, and Smith further teaches the clock derived from a master system clock. |
19315482_6 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 1 (An audio device for wireless audio playback, comprising: a wireless receiver configured to receive a sequence of audio blocks from a source device; a replay buffer configured to: store the sequence of audio blocks; det... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 1, and Smith further teaches the output stage with speaker. |
19315482_7 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 1 (An audio device for wireless audio playback, comprising: a wireless receiver configured to receive a sequence of audio blocks from a source device; a replay buffer configured to: store the sequence of audio blocks; det... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 1, and Smith further teaches the audio device integrated with a gaming console. |
19315482_10 | The following claim is rejected based on the following prior art:
Claim: The method of claim 10 (A method for concealing dropped audio blocks, comprising: receiving, at an audio device, a sequence of audio blocks over a wireless network; buffering the audio blocks in a replay buffer; retrieving a previous audio block i... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 10, and Smith further teaches the wireless speaker. |
19315482_11 | The following claim is rejected based on the following prior art:
Claim: The method of claim 10 (A method for concealing dropped audio blocks, comprising: receiving, at an audio device, a sequence of audio blocks over a wireless network; buffering the audio blocks in a replay buffer; retrieving a previous audio block i... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 10, and Smith further teaches identifying gaps in the data stream. |
19315482_12 | The following claim is rejected based on the following prior art:
Claim: The method of claim 10 (A method for concealing dropped audio blocks, comprising: receiving, at an audio device, a sequence of audio blocks over a wireless network; buffering the audio blocks in a replay buffer; retrieving a previous audio block i... | ['US20030194004A1'] | It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine the teachings of a replay buffer configured to select filter coefficients from a plurality of octave-based frequency bands, as taught by Srinivasan, with the system as taught by Smith in v... |
19315482_13 | The following claim is rejected based on the following prior art:
Claim: The method of claim 10 (A method for concealing dropped audio blocks, comprising: receiving, at an audio device, a sequence of audio blocks over a wireless network; buffering the audio blocks in a replay buffer; retrieving a previous audio block i... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 10, and Smith further teaches video processing pipeline outputs to a display device. |
19315482_14 | The following claim is rejected based on the following prior art:
Claim: The method of claim 10 (A method for concealing dropped audio blocks, comprising: receiving, at an audio device, a sequence of audio blocks over a wireless network; buffering the audio blocks in a replay buffer; retrieving a previous audio block i... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 10, and Smith further teaches the scaling process to bring the amplitude to zero when error-free audio is not detected. |
19315482_16 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 16 (An audio device, comprising: a processor configured to execute a set of instructions; a memory configured to store the set of instructions wherein when executed by the processor of the audio device to: receive a seque... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 16, and Smith further teaches the wireless adapter including Bluetooth module. |
19315482_17 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 16 (An audio device, comprising: a processor configured to execute a set of instructions; a memory configured to store the set of instructions wherein when executed by the processor of the audio device to: receive a seque... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 16, and Smith further teaches synchronization based on master system clock. |
19315482_19 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 16 (An audio device, comprising: a processor configured to execute a set of instructions; a memory configured to store the set of instructions wherein when executed by the processor of the audio device to: receive a seque... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 16, and Smith further teaches the scaling process to bring the amplitude to zero when error-free audio is not detected. |
19313278_0 | The following claim is rejected based on the following prior art:
Claim: A negative electrode active material, comprising: a negative electrode active substance and a coating layer, wherein the coating layer is coated on a surface of the negative electrode active substance, and the coating layer comprises at least one ... | ['US20150188127A1'] | Niimi anticipates all elements of claim 1 by teaching a negative electrode active material with a carbonaceous coating substance formed from polymethyl methacrylate (PMMA) coated on the surface of negative electrode active material particles. |
19313278_1 | The following claim is rejected based on the following prior art:
Claim: The negative electrode active material according to claim 1 (A negative electrode active material, comprising: a negative electrode active substance and a coating layer, wherein the coating layer is coated on a surface of the negative electrode ac... | ['US20150188127A1'] | Niimi anticipates the silicon-based material limitations by teaching lithium silicate, SiOx particles, and Si particles as negative electrode active materials. |
19313278_2 | The following claim is rejected based on the following prior art:
Claim: A negative electrode plate, comprising the negative electrode active material according to claim 1 (A negative electrode active material, comprising: a negative electrode active substance and a coating layer, wherein the coating layer is coated on... | ['US20150188127A1'] | Niimi anticipates the negative electrode plate by teaching a negative electrode made by adhering the negative-electrode active material onto a current collector. |
19313278_3 | The following claim is rejected based on the following prior art:
Claim: A battery cell, comprising the negative electrode plate according to claim 15 (A negative electrode plate, comprising the negative electrode active material according to claim 1 (A negative electrode active material, comprising: a negative electro... | ['US20150188127A1'] | Niimi anticipates the battery cell by teaching that a nonaqueous-electrolyte secondary battery comprises battery constituent elements including the negative electrode, positive electrode, separator, and electrolytic solution. |
19313278_4 | The following claim is rejected based on the following prior art:
Claim: A battery, comprising the battery cell according to claim 16 (A battery cell, comprising the negative electrode plate according to claim 15 (A negative electrode plate, comprising the negative electrode active material according to claim 1 (A nega... | ['US20150188127A1'] | Niimi anticipates the battery by teaching a nonaqueous-electrolyte secondary battery. |
19313278_5 | The following claim is rejected based on the following prior art:
Claim: An electrical device, comprising the battery according to claim 17 (A battery, comprising the battery cell according to claim 16 (A battery cell, comprising the negative electrode plate according to claim 15 (A negative electrode plate, comprising... | ['US20150188127A1'] | Niimi anticipates the electrical device by teaching that lithium-ion secondary batteries are used as a power source for portable electronic devices. |
19313405_0 | The following claim is rejected based on the following prior art:
Claim: A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic surfactant having a hydrophilic-lipoph... | ['US20170114017A1', 'US20110312973A1', 'US20110086844A1'] | It would have been obvious to prepare a solid solution comprising compound 1, 20%-70% of a surfactant such as Cremophor EL and 5%-70% of PEG-4000 because solid solution formulation provides enhanced bio-availability of an active substance in a homogeneous and thermodynamically stable solid solution as suggested by Gori... |
19313405_1 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110086844A1'] | Since prior art teaches active ingredient from 0.1-50%, 2% of active compound 1 is obvious, then 98% of vehicle comprising surfactant macrogol-40-glycerol hydroxystearate and polymer PEG-4000 is obtained from simple calculation. |
19313405_2 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110086844A1'] | Since prior art teaches active ingredient from 0.1-50%, 2% of active compound 1 is obvious, then 98% of vehicle comprising surfactant macrogol-40-glycerol hydroxystearate and polymer PEG-4000 is obtained from simple calculation. |
19313405_3 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110086844A1'] | Since prior art teaches active ingredient from 0.1-50%, 2% of active compound 1 is obvious. |
19313405_4 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110086844A1'] | Since prior art teaches active ingredient from 0.1-50%, 2% of active compound 1 is obvious. |
19313405_5 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110086844A1'] | Since prior art teaches 20%-70% of macrogol-40-glycerol hydroxystearate and 5%-70% of PEG-4000, their ratio of about 50:50 is obvious, and ratios within 30:70 to 65:35 fall within the overlapping ranges. |
19313405_6 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110086844A1'] | Since prior art teaches 20%-70% of macrogol-40-glycerol hydroxystearate and 5%-70% of PEG-4000, their ratio of about 50:50 is obvious, and ratios within 35:65 to 65:35 fall within the overlapping ranges. |
19313405_7 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110086844A1'] | Since prior art teaches 20%-70% of macrogol-40-glycerol hydroxystearate and 5%-70% of PEG-4000, their ratio of about 50:50 is obvious, and ratios within 40:60 to 60:40 fall within the overlapping ranges. |
19313405_8 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110086844A1'] | Since prior art teaches 20%-70% of macrogol-40-glycerol hydroxystearate and 5%-70% of PEG-4000, their ratio of about 50:50 is obvious. |
19313405_9 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110086844A1'] | Since prior art teaches 20%-70% of macrogol-40-glycerol hydroxystearate and 5%-70% of PEG-4000, their ratio of about 50:50 is obvious. |
19313405_10 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110312973A1'] | Liepold teaches Cremophor RH 40 (macrogol-40-glycerol hydroxystearate) is alternative to Cremophor EL and suitable surfactant in solid solution, it is obvious to replace Cremophor RH 40 for Cremophor EL as surfactant in solid solution as simple substitution of one known element for another yields predictable results. |
19313405_11 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110312973A1'] | Liepold teaches Cremophor RH 40 (macrogol-40-glycerol hydroxystearate) is alternative to Cremophor EL and suitable surfactant in solid solution, it is obvious to replace Cremophor RH 40 for Cremophor EL as surfactant in solid solution as simple substitution of one known element for another yields predictable results. |
19313405_12 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110312973A1', 'US20110086844A1'] | Prior art teaches PEG-4000 and PEG-6000 as suitable hydrophilic polymers in solid solution formulations. |
19313405_13 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110312973A1', 'US20110086844A1'] | Prior art teaches PEG-4000 as a suitable hydrophilic polymer in solid solution formulations. |
19313405_14 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110312973A1'] | Liepold teaches both macrogol-40-glycerol hydroxystearate as suitable surfactant and PEG-4000 as suitable hydrophilic polymer in solid solution formulations. |
19313405_15 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20170114017A1'] | Since Fan teaches dosage unit forms containing between 1 mg to 500 mg of active ingredient, for 10 mg of compound 1 at 2% of solid solution, the total amount of solid solution is 500mg, which falls within the claimed range of 130 mg to 900 mg. |
19313405_16 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20170114017A1'] | Since Fan teaches dosage unit forms containing between 1 mg to 500 mg of active ingredient, for 10 mg of compound 1 at 2% of solid solution, the total amount of solid solution is 500mg. |
19313405_17 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110312973A1', 'US20110086844A1'] | Since prior art teaches active ingredient from 0.1-50%, 2% of active compound 1 is obvious, then 98% of vehicle is obtained from simple calculation. Since prior art teaches 20%-70% of macrogol-40-glycerol hydroxystearate and 5%-70% of PEG-4000, their ratio of about 50:50 is obvious. |
19313405_18 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20170114017A1'] | Since Fan teaches dosage unit forms containing between 1 mg to 500 mg of active ingredient, for 10 mg of compound 1 at 2% of solid solution, the total amount of solid solution is 500mg, which is the amount to fill capsule size #0 (capsule size #0 is known to hold about 500mg). |
19313405_19 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20170114017A1', 'US20110086844A1'] | Both Fan and Gorissen teach hard gelatin capsules as suitable dosage forms. |
19313405_20 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 6 (The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a ve... | ['US20110312973A1'] | Liepold teaches Cremophor RH 40 (macrogol-40-glycerol hydroxystearate) is alternative to Cremophor EL and suitable surfactant in solid solution. |
19313405_21 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 6 (The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a ve... | ['US20110312973A1'] | Liepold teaches PEG-4000 as a preferred hydrophilic polymer in solid solution formulations. |
19313405_22 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 6 (The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a ve... | ['US20110312973A1'] | Liepold teaches both macrogol-40-glycerol hydroxystearate as suitable surfactant and PEG-4000 as suitable hydrophilic polymer in solid solution formulations. |
19313405_23 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 7 (The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a ve... | ['US20110312973A1'] | Liepold teaches Cremophor RH 40 (macrogol-40-glycerol hydroxystearate) is alternative to Cremophor EL and suitable surfactant in solid solution. |
19313405_24 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 7 (The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a ve... | ['US20110312973A1'] | Liepold teaches PEG-4000 as a preferred hydrophilic polymer in solid solution formulations. |
19313405_25 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 7 (The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a ve... | ['US20110312973A1'] | Liepold teaches both macrogol-40-glycerol hydroxystearate as suitable surfactant and PEG-4000 as suitable hydrophilic polymer in solid solution formulations. |
19315482_1 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 1 (An audio device for wireless audio playback, comprising: a wireless receiver configured to receive a sequence of audio blocks from a source device; a replay buffer configured to: store the sequence of audio blocks; det... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 1, and Smith further teaches the wireless transceiver limitation. |
19315482_2 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 1 (An audio device for wireless audio playback, comprising: a wireless receiver configured to receive a sequence of audio blocks from a source device; a replay buffer configured to: store the sequence of audio blocks; det... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 1, and Smith further teaches the replay buffer storing multiple audio blocks. |
19315482_3 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 1 (An audio device for wireless audio playback, comprising: a wireless receiver configured to receive a sequence of audio blocks from a source device; a replay buffer configured to: store the sequence of audio blocks; det... | ['US20030194004A1'] | It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine the teachings of a replay buffer configured to select filter coefficients from a plurality of octave-based frequency bands, as taught by Srinivasan, with the system as taught by Smith in v... |
19315482_4 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 1 (An audio device for wireless audio playback, comprising: a wireless receiver configured to receive a sequence of audio blocks from a source device; a replay buffer configured to: store the sequence of audio blocks; det... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 1, and Smith further teaches the fade-to-zero when error-free audio block is not detected, scaling the replacement blocks down in steps until reaching zero. |
19315482_5 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 1 (An audio device for wireless audio playback, comprising: a wireless receiver configured to receive a sequence of audio blocks from a source device; a replay buffer configured to: store the sequence of audio blocks; det... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 1, and Smith further teaches the clock derived from a master system clock. |
19315482_6 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 1 (An audio device for wireless audio playback, comprising: a wireless receiver configured to receive a sequence of audio blocks from a source device; a replay buffer configured to: store the sequence of audio blocks; det... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 1, and Smith further teaches the output stage with speaker. |
19315482_7 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 1 (An audio device for wireless audio playback, comprising: a wireless receiver configured to receive a sequence of audio blocks from a source device; a replay buffer configured to: store the sequence of audio blocks; det... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 1, and Smith further teaches the audio device integrated with a gaming console. |
19315482_10 | The following claim is rejected based on the following prior art:
Claim: The method of claim 10 (A method for concealing dropped audio blocks, comprising: receiving, at an audio device, a sequence of audio blocks over a wireless network; buffering the audio blocks in a replay buffer; retrieving a previous audio block i... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 10, and Smith further teaches the wireless speaker. |
19315482_11 | The following claim is rejected based on the following prior art:
Claim: The method of claim 10 (A method for concealing dropped audio blocks, comprising: receiving, at an audio device, a sequence of audio blocks over a wireless network; buffering the audio blocks in a replay buffer; retrieving a previous audio block i... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 10, and Smith further teaches identifying gaps in the data stream. |
19315482_12 | The following claim is rejected based on the following prior art:
Claim: The method of claim 10 (A method for concealing dropped audio blocks, comprising: receiving, at an audio device, a sequence of audio blocks over a wireless network; buffering the audio blocks in a replay buffer; retrieving a previous audio block i... | ['US20030194004A1'] | It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine the teachings of a replay buffer configured to select filter coefficients from a plurality of octave-based frequency bands, as taught by Srinivasan, with the system as taught by Smith in v... |
19315482_13 | The following claim is rejected based on the following prior art:
Claim: The method of claim 10 (A method for concealing dropped audio blocks, comprising: receiving, at an audio device, a sequence of audio blocks over a wireless network; buffering the audio blocks in a replay buffer; retrieving a previous audio block i... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 10, and Smith further teaches video processing pipeline outputs to a display device. |
19315482_14 | The following claim is rejected based on the following prior art:
Claim: The method of claim 10 (A method for concealing dropped audio blocks, comprising: receiving, at an audio device, a sequence of audio blocks over a wireless network; buffering the audio blocks in a replay buffer; retrieving a previous audio block i... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 10, and Smith further teaches the scaling process to bring the amplitude to zero when error-free audio is not detected. |
19315482_16 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 16 (An audio device, comprising: a processor configured to execute a set of instructions; a memory configured to store the set of instructions wherein when executed by the processor of the audio device to: receive a seque... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 16, and Smith further teaches the wireless adapter including Bluetooth module. |
19315482_17 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 16 (An audio device, comprising: a processor configured to execute a set of instructions; a memory configured to store the set of instructions wherein when executed by the processor of the audio device to: receive a seque... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 16, and Smith further teaches synchronization based on master system clock. |
19315482_19 | The following claim is rejected based on the following prior art:
Claim: The audio device of claim 16 (An audio device, comprising: a processor configured to execute a set of instructions; a memory configured to store the set of instructions wherein when executed by the processor of the audio device to: receive a seque... | ['US20080312932A1'] | Smith in view of Higashiyama teaches all the limitations of claim 16, and Smith further teaches the scaling process to bring the amplitude to zero when error-free audio is not detected. |
19313278_0 | The following claim is rejected based on the following prior art:
Claim: A negative electrode active material, comprising: a negative electrode active substance and a coating layer, wherein the coating layer is coated on a surface of the negative electrode active substance, and the coating layer comprises at least one ... | ['US20150188127A1'] | Niimi anticipates all elements of claim 1 by teaching a negative electrode active material with a carbonaceous coating substance formed from polymethyl methacrylate (PMMA) coated on the surface of negative electrode active material particles. |
19313278_1 | The following claim is rejected based on the following prior art:
Claim: The negative electrode active material according to claim 1 (A negative electrode active material, comprising: a negative electrode active substance and a coating layer, wherein the coating layer is coated on a surface of the negative electrode ac... | ['US20150188127A1'] | Niimi anticipates the silicon-based material limitations by teaching lithium silicate, SiOx particles, and Si particles as negative electrode active materials. |
19313278_2 | The following claim is rejected based on the following prior art:
Claim: A negative electrode plate, comprising the negative electrode active material according to claim 1 (A negative electrode active material, comprising: a negative electrode active substance and a coating layer, wherein the coating layer is coated on... | ['US20150188127A1'] | Niimi anticipates the negative electrode plate by teaching a negative electrode made by adhering the negative-electrode active material onto a current collector. |
19313278_3 | The following claim is rejected based on the following prior art:
Claim: A battery cell, comprising the negative electrode plate according to claim 15 (A negative electrode plate, comprising the negative electrode active material according to claim 1 (A negative electrode active material, comprising: a negative electro... | ['US20150188127A1'] | Niimi anticipates the battery cell by teaching that a nonaqueous-electrolyte secondary battery comprises battery constituent elements including the negative electrode, positive electrode, separator, and electrolytic solution. |
19313278_4 | The following claim is rejected based on the following prior art:
Claim: A battery, comprising the battery cell according to claim 16 (A battery cell, comprising the negative electrode plate according to claim 15 (A negative electrode plate, comprising the negative electrode active material according to claim 1 (A nega... | ['US20150188127A1'] | Niimi anticipates the battery by teaching a nonaqueous-electrolyte secondary battery. |
19313278_5 | The following claim is rejected based on the following prior art:
Claim: An electrical device, comprising the battery according to claim 17 (A battery, comprising the battery cell according to claim 16 (A battery cell, comprising the negative electrode plate according to claim 15 (A negative electrode plate, comprising... | ['US20150188127A1'] | Niimi anticipates the electrical device by teaching that lithium-ion secondary batteries are used as a power source for portable electronic devices. |
19313405_0 | The following claim is rejected based on the following prior art:
Claim: A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic surfactant having a hydrophilic-lipoph... | ['US20170114017A1', 'US20110312973A1', 'US20110086844A1'] | It would have been obvious to prepare a solid solution comprising compound 1, 20%-70% of a surfactant such as Cremophor EL and 5%-70% of PEG-4000 because solid solution formulation provides enhanced bio-availability of an active substance in a homogeneous and thermodynamically stable solid solution as suggested by Gori... |
19313405_1 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110086844A1'] | Since prior art teaches active ingredient from 0.1-50%, 2% of active compound 1 is obvious, then 98% of vehicle comprising surfactant macrogol-40-glycerol hydroxystearate and polymer PEG-4000 is obtained from simple calculation. |
19313405_2 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110086844A1'] | Since prior art teaches active ingredient from 0.1-50%, 2% of active compound 1 is obvious, then 98% of vehicle comprising surfactant macrogol-40-glycerol hydroxystearate and polymer PEG-4000 is obtained from simple calculation. |
19313405_3 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110086844A1'] | Since prior art teaches active ingredient from 0.1-50%, 2% of active compound 1 is obvious. |
19313405_4 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110086844A1'] | Since prior art teaches active ingredient from 0.1-50%, 2% of active compound 1 is obvious. |
19313405_5 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110086844A1'] | Since prior art teaches 20%-70% of macrogol-40-glycerol hydroxystearate and 5%-70% of PEG-4000, their ratio of about 50:50 is obvious, and ratios within 30:70 to 65:35 fall within the overlapping ranges. |
19313405_6 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110086844A1'] | Since prior art teaches 20%-70% of macrogol-40-glycerol hydroxystearate and 5%-70% of PEG-4000, their ratio of about 50:50 is obvious, and ratios within 35:65 to 65:35 fall within the overlapping ranges. |
19313405_7 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110086844A1'] | Since prior art teaches 20%-70% of macrogol-40-glycerol hydroxystearate and 5%-70% of PEG-4000, their ratio of about 50:50 is obvious, and ratios within 40:60 to 60:40 fall within the overlapping ranges. |
19313405_8 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110086844A1'] | Since prior art teaches 20%-70% of macrogol-40-glycerol hydroxystearate and 5%-70% of PEG-4000, their ratio of about 50:50 is obvious. |
19313405_9 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110086844A1'] | Since prior art teaches 20%-70% of macrogol-40-glycerol hydroxystearate and 5%-70% of PEG-4000, their ratio of about 50:50 is obvious. |
19313405_10 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110312973A1'] | Liepold teaches Cremophor RH 40 (macrogol-40-glycerol hydroxystearate) is alternative to Cremophor EL and suitable surfactant in solid solution, it is obvious to replace Cremophor RH 40 for Cremophor EL as surfactant in solid solution as simple substitution of one known element for another yields predictable results. |
19313405_11 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110312973A1'] | Liepold teaches Cremophor RH 40 (macrogol-40-glycerol hydroxystearate) is alternative to Cremophor EL and suitable surfactant in solid solution, it is obvious to replace Cremophor RH 40 for Cremophor EL as surfactant in solid solution as simple substitution of one known element for another yields predictable results. |
19313405_12 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110312973A1', 'US20110086844A1'] | Prior art teaches PEG-4000 and PEG-6000 as suitable hydrophilic polymers in solid solution formulations. |
19313405_13 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110312973A1', 'US20110086844A1'] | Prior art teaches PEG-4000 as a suitable hydrophilic polymer in solid solution formulations. |
19313405_14 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110312973A1'] | Liepold teaches both macrogol-40-glycerol hydroxystearate as suitable surfactant and PEG-4000 as suitable hydrophilic polymer in solid solution formulations. |
19313405_15 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20170114017A1'] | Since Fan teaches dosage unit forms containing between 1 mg to 500 mg of active ingredient, for 10 mg of compound 1 at 2% of solid solution, the total amount of solid solution is 500mg, which falls within the claimed range of 130 mg to 900 mg. |
19313405_16 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20170114017A1'] | Since Fan teaches dosage unit forms containing between 1 mg to 500 mg of active ingredient, for 10 mg of compound 1 at 2% of solid solution, the total amount of solid solution is 500mg. |
19313405_17 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20110312973A1', 'US20110086844A1'] | Since prior art teaches active ingredient from 0.1-50%, 2% of active compound 1 is obvious, then 98% of vehicle is obtained from simple calculation. Since prior art teaches 20%-70% of macrogol-40-glycerol hydroxystearate and 5%-70% of PEG-4000, their ratio of about 50:50 is obvious. |
19313405_18 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20170114017A1'] | Since Fan teaches dosage unit forms containing between 1 mg to 500 mg of active ingredient, for 10 mg of compound 1 at 2% of solid solution, the total amount of solid solution is 500mg, which is the amount to fill capsule size #0 (capsule size #0 is known to hold about 500mg). |
19313405_19 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a vehicle comprising at least one non-ionic... | ['US20170114017A1', 'US20110086844A1'] | Both Fan and Gorissen teach hard gelatin capsules as suitable dosage forms. |
19313405_20 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 6 (The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a ve... | ['US20110312973A1'] | Liepold teaches Cremophor RH 40 (macrogol-40-glycerol hydroxystearate) is alternative to Cremophor EL and suitable surfactant in solid solution. |
19313405_21 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 6 (The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a ve... | ['US20110312973A1'] | Liepold teaches PEG-4000 as a preferred hydrophilic polymer in solid solution formulations. |
19313405_22 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 6 (The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a ve... | ['US20110312973A1'] | Liepold teaches both macrogol-40-glycerol hydroxystearate as suitable surfactant and PEG-4000 as suitable hydrophilic polymer in solid solution formulations. |
19313405_23 | The following claim is rejected based on the following prior art:
Claim: The solid solution capsule of claim 7 (The solid solution capsule of claim 1 (A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt (Compound 1) and a ve... | ['US20110312973A1'] | Liepold teaches Cremophor RH 40 (macrogol-40-glycerol hydroxystearate) is alternative to Cremophor EL and suitable surfactant in solid solution. |
End of preview. Expand in Data Studio
No dataset card yet
- Downloads last month
- 4